Uterine arteriovenous malformation or uterine artery pseudoaneurysm secondary to uterine aspiration in cesarean scar ectopic pregnancy: a case report and review of the literature

剖宫产瘢痕异位妊娠子宫抽吸术后继发子宫动静脉畸形或子宫动脉假性动脉瘤:病例报告及文献复习

阅读:2

Abstract

INTRODUCTION: Uterine arteriovenous malformation or uterine artery pseudoaneurysm after the treatment of cesarean scar ectopic pregnancy is a scarce entity, leading to potentially life-threatening conditions due to the massive bleeding. The management remains significantly crucial. Herein, we report an uncommon case with surgical management of such a rare condition at our center. PRESENTATION CASE: A 31-year-old Vietnamese female patient (gravida 2, para 1) was hospitalized for cesarean scar pregnancy. The uterine aspiration was well performed. However, the woman was readmitted for an abnormally persistent hypervascularity at the site of cesarean scar ectopic pregnancy under repeated ultrasound scans. After counseling, arteriovenous malformation was suspected more, whereas uterine pseudoaneurysm was incompletely ruled out. Initially, gonadotropin-releasing hormone agonist was administered, with two doses of 37.5 mg. Later, the patient underwent laparoscopic intervention to suture the vascular proliferation mass to prevent spontaneous rupture. The surgery was achieved successfully. One more dose of gonadotropin-releasing hormone agonist was added. The ultrasound detected no existing lesion compared with previous ultrasonic imaging and serum beta-human chorionic gonadotropin declined to a negative value. The patient was monitored in 1 month uneventfully. CONCLUSION: A high index of suspicion of uterine arteriovenous malformation or uterine artery pseudoaneurysm should be raised after uterine curettage of cesarean scar ectopic pregnancy. Ultrasound scan is still a pivotal first-line tool in assessing this abnormality. Laparoscopic surgery with compressing suture of the enhanced myometrial vascularity/arteriovenous malformation combined with administration of gonadotropin-releasing hormone agonist may be applied. This surgical approach has not been reported before, which makes our case report unique. Further cases are required for this rare entity so as to ensure patient safety.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。